Akram Kooshki, Mohammad Reza Memarzadeh, Mohammad Hassan Rakhshani, Roya Akbarzadeh, Tahereh Tofighiyan, Elaheh Foroumandi
{"title":"芦荟补充剂可改善血液透析患者的心血管风险因素：一项随机、双盲、安慰剂对照试验。","authors":"Akram Kooshki, Mohammad Reza Memarzadeh, Mohammad Hassan Rakhshani, Roya Akbarzadeh, Tahereh Tofighiyan, Elaheh Foroumandi","doi":"10.22038/AJP.2023.23447","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.</p><p><strong>Materials and methods: </strong>Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.</p><p><strong>Results: </strong>Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.</p><p><strong>Conclusion: </strong>Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.</p>","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":"14 4","pages":"422-430"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179180/pdf/","citationCount":"0","resultStr":"{\"title\":\"Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.\",\"authors\":\"Akram Kooshki, Mohammad Reza Memarzadeh, Mohammad Hassan Rakhshani, Roya Akbarzadeh, Tahereh Tofighiyan, Elaheh Foroumandi\",\"doi\":\"10.22038/AJP.2023.23447\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.</p><p><strong>Materials and methods: </strong>Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.</p><p><strong>Results: </strong>Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.</p><p><strong>Conclusion: </strong>Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.</p>\",\"PeriodicalId\":8677,\"journal\":{\"name\":\"Avicenna Journal of Phytomedicine\",\"volume\":\"14 4\",\"pages\":\"422-430\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179180/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Avicenna Journal of Phytomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22038/AJP.2023.23447\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2023.23447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.
Objective: This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.
Materials and methods: Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.
Results: Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.
Conclusion: Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
